Beta Finch - S&P 100 - EN

More earnings analysis: https://betafinch.com
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the calls that move markets and make sense of the numbers behind them. I'm Alex.

JORDAN: And I'm Jordan. Today we're digging into Prologis — ticker PLD — the industrial and logistics real estate giant, reporting their second quarter of 2026.

ALEX: Before we jump in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Okay, with that out of the way, Alex, this was a strong quarter for Prologis. Where do we start?

ALEX: Let's start with the headline numbers. Core FFO came in at $1.63 per share including promote income, $1.60 without — both ahead of expectations. And because of that strength, they raised full-year guidance: Core FFO now expected between $6.22 and $6.30 per share, and net earnings guidance up to $4.40 to $4.55 per share.

JORDAN: And it's not just a beat-and-raise on the bottom line — the operational metrics back it up. Occupancy hit 95.5%, up 20 basis points from Q1. Same-store NOI growth was 6.4% net effective and 8.5% on a cash basis. Those are really healthy numbers for a REIT this size.

ALEX: The leasing volume stood out to me the most — 67 million square feet signed in the quarter. CEO Dan Letter called it their fourth record in seven quarters.

JORDAN: Right, and it's paired with 66 million square feet of net absorption in the US, the highest since 2022. Vacancy dropped to 7.2%, market rents ticked up about 70 basis points. Management's whole thesis this call was that the industrial market has moved past its "inflection phase" and into what they're calling the next phase of growth.

ALEX: There's also a really interesting structural story here beyond just warehouses. Prologis has been building out data centers and energy as parallel growth engines using the same land and customer relationships.

JORDAN: Yeah, the numbers there are eye-popping. Their power pipeline is now 5.8 gigawatts — that's more than doubled in two years. Depending on how much of that gets built as basic "powered shell" versus fully finished "turnkey" data centers, that represents somewhere between $17 billion and $87 billion of potential investment.

ALEX: Huge range.

JORDAN: Huge range, and CEO Dan Letter was upfront on the call that it's genuinely hard to predict where in that range they'll land — it depends on customer preference. But they did share they've now started nearly $4 billion of data center development, all build-to-suit for hyperscale customers, and they sold a 100-megawatt power land parcel this quarter at an 82% margin.

ALEX: Which tells you how profitable just the land and power entitlement piece of this business can be, even before construction.

JORDAN: Exactly — and CFO Tim Arndt mentioned they see over 10 gigawatts of opportunity over the next decade. It's basically a second growth business layered on top of the core logistics platform.

ALEX: On the guidance side, they raised development starts to a range of $5.5 to $6.5 billion, and increased acquisitions guidance too — they bought $1.8 billion of real estate this quarter at roughly a 20% discount to replacement cost.

JORDAN: That IRR discipline came up a few times. Management noted underwritten IRRs on acquisitions have beaten IRRs on dispositions by 140 basis points year to date — so they're actively upgrading the portfolio, not just growing for growth's sake.

ALEX: Now, one thing listeners should know — there's a corporate development angle hovering over this whole call that management wouldn't discuss.

JORDAN: Right, Prologis has made a possible offer for Segro, a UK logistics REIT, under UK takeover rules. Because of regulatory restrictions, they explicitly said they couldn't answer any que

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE), INCOME (https://betafinch.com/groups/INCOME)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown. Here's the Abbott Labs (ABT) Q2 2026 script.

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Abbott Laboratories' second quarter 2026 results. Before we jump in, quick disclaimer — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks, Alex. And there's a lot to like in this print. Let's start with the headline numbers.

**ALEX:** Right, so Abbott posted sales growth of 4.8% for the quarter — that's an acceleration from the last two quarters — and adjusted EPS of $1.31, which beat both the midpoint of their guidance and consensus estimates.

**JORDAN:** And here's the part investors really zeroed in on — Abbott didn't just reaffirm full-year sales guidance of 6.5% to 7.5%, they actually raised their EPS guidance range to $5.45 to $5.60. CEO Robert Ford was pretty clear that gross margin expansion is doing a lot of the heavy lifting there — margins came in at 58%, up 100 basis points year-over-year.

**ALEX:** Let's talk segments, because there's a real story of divergence here. Medical devices grew 8.5%, led by electrophysiology — that's the heart rhythm and ablation business — which grew in the low teens. EPD, their emerging markets pharma division, grew 9%, powered by India, Latin America, and Southeast Asia.

**JORDAN:** Diagnostics was mixed. Core lab was strong, U.S. up 7.5%. But rapid and molecular diagnostics — that's respiratory testing — declined 8% because it was just a weak flu and respiratory virus season. That's expected and temporary though, not a demand problem.

**ALEX:** And then nutrition — this is the comeback story of the quarter. Sales came in ahead of expectations for the second straight quarter, up sequentially by $125 million. Ensure retail consumption in the U.S. is up double digits.

**JORDAN:** Yeah, that's the price increases from late last year finally working through the system — volumes are responding well now that consumers have adjusted. Management is now framing nutrition as a sustainable 2-4% grower going forward.

**ALEX:** Let's get into the strategic stuff, because there's a lot of pipeline news. Abbott completed enrollment in its coronary IVL trial, filed with the FDA for the Amulet 360 left atrial appendage device, and got a CE mark in Europe for Libre Duo — which is notable, it's the world's first dual glucose-ketone monitoring sensor, designed to help prevent diabetic ketoacidosis.

**JORDAN:** The CGM story is worth sitting with for a second. Diabetes care crossed $2 billion in quarterly sales, growing 9.5%. Now, one analyst on the call kind of poked at that number as "only" 9.5%, and Ford pushed back — reasonably, I'd say. He pointed out there's 75 to 80 million people globally who could realistically use a CGM, and only 15 million currently do. Growth right now is basically waiting on reimbursement expansion, especially the big one: U.S. Type 2 non-insulin Medicare coverage, which could unlock roughly 10 million beneficiaries. Ford said that could happen this fall but wouldn't pin down an exact date.

**ALEX:** They're also planning a fifth manufacturing facility for CGM sensors — a billion-dollar investment — because they expect to hit capacity limits at their current facility within a couple years. That's a pretty strong signal of how bullish they are on long-term demand.

**JORDAN:** One theme that came up repeatedly in the Q&A was this investor worry about decelerating hospital procedure volumes — tied to ACA enrollment changes and Medicaid dynamics.

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown of the companies moving the market. I'm about to walk through GE Aerospace's Q2 2026 results.

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, here with Jordan, and today we're digging into GE Aerospace's second quarter 2026 numbers. Before we get into it — quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And GE Aerospace gave us a lot to talk about this quarter, Alex. This wasn't just a beat — they raised guidance across the board.

ALEX: Right, let's start with the headline numbers. Orders up 17%, revenue up 24% — that's the fifth straight quarter of at least 20% revenue growth — operating profit up 18%, EPS up 22% to $2.02, and free cash flow jumped 43% to $3 billion.

JORDAN: That free cash flow number really stood out to me. They actually reduced working capital even while earnings grew 24%. CFO Rahul Ghai called that out specifically — better receivables, better inventory management. That's not easy to pull off when you're scaling this fast.

ALEX: And both segments contributed. Commercial Engines and Services, or CES, was up 27% in revenue, and Defense and Propulsion, DPT, grew 16%. CES margins did dip about 130 basis points to 21.7%, but that's from investing in installed engine growth — basically the cost of feeding future services revenue.

JORDAN: Which is the classic GE Aerospace story right now — sell more engines at lower margin today, because those engines come back for decades of high-margin maintenance work. Their backlog is over $210 billion total, with $170 billion of that in commercial services alone.

ALEX: So given all that strength, they raised full-year guidance pretty significantly. Revenue now expected to grow high teens, up from low double digits. EPS guidance moved to $7.65 to $7.85, and free cash flow guidance jumped to $8.9 to $9.2 billion.

JORDAN: What's interesting is CEO Larry Culp explained why they didn't raise guidance last quarter despite a strong Q1 — there was real geopolitical and demand uncertainty back in April. He said flat out, "we would play April all over again in the same way." They wanted to see how customer behavior actually played out before getting ahead of themselves.

ALEX: And it turns out demand held up remarkably well. Culp mentioned parked CFM56 aircraft have actually declined since March, and departures — which were roughly flat in the first half — are expected to gradually pick back up in the second half.

JORDAN: The demand side really isn't the constraint here anymore. Multiple times on the call, both Culp and Ghai said this is now a supply-side story, not a demand-side one. Spare parts delinquencies — meaning shipments delayed due to material availability — were actually up 20% sequentially, even as they're growing spare parts revenue over 25%.

ALEX: That's a good problem to have, but still a real constraint. They talked about using their "Flight Deck" operational system to chip away at it — things like a Kaizen event with supplier GKN that led to a 90% improvement in inspection time, and AI-driven demand signal processing that cut processing time by nearly 90% across 190 parts.

JORDAN: And on the product side, a big milestone — they certified the LEAP-1B durability kit, which should roughly double time on wing. That's huge for airlines worried about engine cost of ownership, which came up multiple times in the Q&A. Analysts pushed hard on whether airlines can keep absorbing these costs.

ALEX: Culp's answer was essentially: we hear you, we're not taking a victory lap, but we're doing everything we can short-term — like getting LEAP

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: BANKS (https://betafinch.com/groups/BANKS)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Morgan Stanley's second quarter 2026 results — and Jordan, this one's got some genuinely eye-popping numbers.

JORDAN: It really does. But before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Right, let's get into it. Morgan Stanley posted record revenues of $21.3 billion for the quarter, with EPS of $3.46 — both records. First half of the year, they're at $42 billion in revenue and a 27% return on tangible common equity. That's an exceptional run.

JORDAN: And it wasn't just one business carrying the load. Institutional Securities hit a record $11 billion in revenue, driven by an absolutely blowout equities quarter — $6.3 billion, up across every product and region, with Asia standing out. Investment banking revenue jumped 58% year-over-year to $2.4 billion.

ALEX: That IPO market really came alive this quarter too, which fed directly into Wealth Management. They added a record $148 billion in net new assets — and CFO Sharon Yeshaya pointed out that stock plan and IPO flows made up just over half of that. Total client assets across Wealth and Investment Management now sit at $10 trillion, which CEO Ted Pick called out as a milestone the firm's been chasing for a while.

JORDAN: The wealth management pre-tax margin came in at 30.5%, also a record. And there was a nice shareholder-friendly move — a 15% dividend increase to $1.15 per share, plus $1.5 billion in buybacks. Their CET1 capital ratio is at 14.8%, giving them roughly 300 basis points of excess capital cushion.

ALEX: That capital question actually drove one of the more interesting exchanges in the Q&A. An analyst asked Pick point blank — why keep sitting on all this excess capital instead of deploying it more aggressively? His answer was basically: there's real client demand for that capital across every business line, and they'd rather feed the organic growth machine first. He didn't rule out bolt-on acquisitions, but said the bias is clearly toward organic investment right now.

JORDAN: The moment that stood out most to me, though, was when Mike Mayo asked about the AI capital expenditure supercycle. Pick actually put real numbers on it — data center CapEx forecasts for 2026 have jumped from an initial $575 billion estimate to about $850 billion actually coming in. For 2027, projections have gone from $700 billion to $1.3 trillion. And he floated a longer-term thesis, using their research team's framework, that the AI compute buildout could eventually reach something like $10 trillion — but stressed we're only maybe 10 to 15% of the way through that cycle.

ALEX: He was pretty careful to caveat that, though — called it a "known unknown" and said the numbers could shift dramatically based on chip innovation, geopolitics, supply chains. He wasn't trying to make it sound like a sure thing.

JORDAN: Right, and that ties into the second big theme he flagged — the return of geopolitics as a force reshaping supply chains and capital allocation. When Gerard Cassidy asked what could make this AI-driven boom crack, Pick's answer was refreshingly candid — he referenced the dot-com bubble and the SPAC boom, and said the firm's watching closely for froth. Their mantra, as he put it, is "higher highs, but also higher lows" — meaning they want durability, not just a hot quarter.

ALEX: On the wealth management side, there was also a good exchange about competition. Steven Chubak asked about smaller RIAs undercutting on price to win workplace clients. Sharon's response was essentially: scale is the moat. Corporate relationships, the breadth o

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Johnson & Johnson's second quarter 2026 results, and Jordan, there's a lot to unpack here.

JORDAN: There really is. But first, the fine print — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Right, so let's get into it. J&J posted $25.3 billion in quarterly sales, up 5.6% operationally. That doesn't sound huge until you realize they absorbed a 460 basis point headwind from STELARA losing patent protection to biosimilars.

JORDAN: Yeah, strip out STELARA and the rest of the business grew double digits. That's the real story. Net earnings came in at $5.5 billion, diluted EPS of $2.27, and on an adjusted basis, EPS was $2.90, up nearly 5% year-over-year. And here's the kicker — they raised full-year guidance. Operational sales growth now expected at 6.5% to 7.1%, and adjusted EPS guidance moved up to $11.50-$11.65.

ALEX: They're also closing in on a milestone — more than $100 billion in annual revenue for the first time in the company's 140-year history.

JORDAN: Which is wild to say out loud. This is a company with 28 different products or platforms each doing over a billion dollars a year. That's not a one-hit-wonder portfolio, that's just breadth everywhere.

ALEX: Let's talk oncology, because that's really where J&J flexed this quarter. DARZALEX, their multiple myeloma drug, did over $4 billion, up almost 18%. But the newer combo therapies are what caught my eye — CARVYKTI up 47.7%, TECVAYLI up 56%, TALVEY up 62.6%.

JORDAN: Those growth rates on top of an already-dominant multiple myeloma franchise are pretty remarkable. And they're not resting — new data showed the TALVEY-DARZALEX combo keeping over 80% of patients progression-free at two years, with overall survival up to 89%. That's the kind of data that extends a franchise's life for years.

ALEX: Then there's the newer launches — ICOTYDE in psoriasis, INLEXZO in bladder cancer, RYBREVANT in lung and now head-and-neck cancer. ICOTYDE in particular is getting a lot of attention. Over 11,000 patients started therapy, 6,000 unique prescribers, and more than half of commercial payers already covering it within 90 days.

JORDAN: What's interesting is how they're positioning it alongside TREMFYA, which by the way had a monster quarter — 71% growth, its first $2 billion quarter. Instead of cannibalizing each other, management's framing ICOTYDE as the go-to first systemic treatment and TREMFYA as the first-choice biologic, especially for patients trending toward psoriatic arthritis. It's a two-pronged attack on the same disease area.

ALEX: Now, MedTech was the softer spot this quarter — only 3.6% growth. Cardiovascular was the drag, mainly Abiomed's heart pump business.

JORDAN: Right, and this is worth unpacking because it wasn't a demand problem. A neutral clinical trial out of the U.K. made physicians more cautious about patient selection for Impella devices, so usage slowed. Management was pretty direct about it — they called it a "behavioral" issue, not structural. They're leaning on their own much larger evidence base, over 40,000 patients studied versus the UK trial's 300, while they wait for their own PROTECT IV trial data, which won't read out until 2027.

ALEX: Meanwhile, three of MedTech's four businesses — surgery, vision, and orthopedics — actually accelerated and beat expectations. So it's really one segment, heart recovery, dragging on an otherwise solid MedTech story.

JORDAN: And there's real excitement building around the robotics pipeline — the OTTAVA surgical robot and MONARCH for urology are both awaiti

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: BANKS (https://betafinch.com/groups/BANKS)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into BlackRock's second quarter 2026 numbers — and Jordan, this was a genuinely loud quarter.

JORDAN: Loud is the right word. Record revenue, record operating income, record EPS, all in the same three months.

ALEX: Before we get into it, a quick note. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good, let's get into it. Revenue came in at $7.1 billion, up 31% year-over-year. Operating income jumped 39% to $2.9 billion, and EPS hit $13.91.

ALEX: And the margin story is what jumped out to me. 45.9% operating margin, up 260 basis points from a year ago — that's their best level in almost five years.

JORDAN: Right, and CFO Martin Small was pretty clear that 45.9% isn't a ceiling. He pointed out BlackRock ran near 47% margins back in 2021, before they even had the scale in private markets or systematic equities they have now. So there's an argument the runway keeps going.

ALEX: Let's talk flows, because $192 billion of net inflows in a single quarter is enormous. That's 8% organic base fee growth for the quarter, and over the trailing twelve months they've pulled in $868 billion with 10% organic base fee growth.

JORDAN: iShares ETFs led the way — $178 billion of inflows, with core equity ETFs at $85 billion and index bond ETFs setting a new record at $61 billion. Active ETFs added another $20 billion, and Larry Fink noted BlackRock has gone from the seventh-largest active ETF manager to third-largest in just three years.

ALEX: The other big storyline is the HPS and GIP integration — the private markets acquisitions that closed about a year ago. Fink said the combination is already "delivering above our plans."

JORDAN: The numbers back that up. HPS alone contributed about $230 million in base fees and $115 million in performance fees this quarter. And on the insurance side, Fink talked about converting general account assets — they've got roughly $800 billion of insurance assets on the platform — into higher-yielding private markets allocations. Even a 5-10% conversion rate, he said, would be a meaningful lift to average fees.

ALEX: There was also that data center deal — Aligned Data Centers — described as the largest data center infrastructure transaction ever announced, bringing together their AIP, GIP, and MGX platforms.

JORDAN: That ties into a theme across the whole call: hyperscalers needing balance-sheet partners to build out AI infrastructure, and BlackRock positioning itself as one of the few firms that can show up with both equity and debt capital at scale.

ALEX: Let's hit tokenization for a second, because Martin Small got pretty specific here. They've filed two SEC registration statements for tokenized money market funds — one a tokenized share class on Ethereum, the other a more digitally native version with features like daily dividend reinvestment.

JORDAN: And the framing was interesting — he called tokenized assets "the spear tip into an entirely new distribution channel," pointing to the roughly 5 billion digital wallets globally as a pool of potential new iShares investors. They're also already managing $60 billion in stablecoin reserves for Circle, about a quarter of that market.

ALEX: On the capital return side, they bumped up guidance — now planning at least $550 million in quarterly share buybacks, higher than what they guided back in January. Combined with the dividend, they're expecting to return over $5.7 billion to shareholders this year, a 16% increase over 2025.

JORDAN: One thing worth flagging for listeners: EPS growth of 15% was actually a bit lower than the 39% operating income growth

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: BANKS (https://betafinch.com/groups/BANKS)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, here with Jordan, and today we're diving into Wells Fargo's second quarter 2026 results. Before we jump in — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And Alex, this was a genuinely strong quarter for Wells Fargo. Diluted EPS hit $2, up 25% year-over-year. Revenue grew 9%. Every single operating segment posted growth in both net interest income and non-interest income.

ALEX: That broad-based part is what jumps out to me. CEO Charlie Scharf made a point of saying it's not just a rising-rate-environment story — it's investments and operating discipline paying off. Headcount has now declined for 24 straight quarters, down to 197,000, while they're actually adding bankers, advisors, and traders in growth areas.

JORDAN: Right, they're funding growth with efficiency savings rather than just cutting costs across the board. And the returns numbers back it up — ROTCE jumped to 17.7% this quarter, up from 15.2% a year ago. CFO Mike Santomassimo did flag that venture capital gains — $847 million in equity gains — juiced that number a bit, but even stripping that out, the underlying trend is improving.

ALEX: Wells Fargo has a medium-term target of 17-18% ROTCE, and Scharf was asked repeatedly about timing on that. His answer, essentially: "we're more confident every quarter, but we're not giving you a hard date because rates and markets are unpredictable."

JORDAN: Classic executive hedge, but a reasonable one. Let's talk net interest income, because that's where most of the analyst questions went. Full-year guidance stayed at $50 billion, give or take, but the composition shifted a little — loan growth is coming in better than expected, while non-interest-bearing deposits aren't growing as much as they'd hoped.

ALEX: And net interest margin actually compressed again — down 4 basis points from Q1. Management's explanation is interesting: it's largely self-inflicted, in a good way. They're growing their markets business balance sheet aggressively, financing clients at lower spreads, which drags down NIM but drives higher trading revenue and deeper relationships.

JORDAN: Scharf was pretty emphatic about that point — he said NIM compression "is not happening to us," it's a deliberate choice they can reverse if the payoff isn't there. Markets revenue grew 24% year-over-year, so early signs suggest it's working. They expect a bit more NIM pressure in Q3, then stabilization in Q4.

ALEX: Loan and deposit growth were both double-digit — average loans up 12%, deposits up 10% — which is a big deal since Wells Fargo only got out from under the Fed's asset cap last year. They're finally playing offense after years of being constrained.

JORDAN: Credit quality remained a bright spot too. Net charge-offs declined 10 basis points year-over-year to 34 basis points. Consumer delinquencies are actually coming in better than their models predict. Commercial credit is clean as well, though Scharf did flag caution around wholesale lending — data center financing, leveraged deals — where non-bank lenders are taking on more risk than Wells is willing to.

ALEX: That data center commentary was one of my favorite exchanges. An analyst asked about second-derivative AI exposure, and Scharf gave a really thoughtful answer about how they underwrite different pieces of the data center supply chain differently — chip makers get paid back fast with huge margins, but other players in the chain carry much longer, riskier payback horizons.

JORDAN: It showed real discipline — they're not just chasing the AI infrastructure boom blindly. On the business-line side, the Cor

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: BANKS (https://betafinch.com/groups/BANKS)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take a dense earnings call transcript and turn it into something you can actually enjoy with your coffee. I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into JPMorgan Chase, ticker JPM, Q2 2026 results — and Alex, this one had a little bit of everything: blowout numbers, a leadership shakeup, and Jamie Dimon being Jamie Dimon.

ALEX: Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good, glad that's out of the way. So let's start with the headline numbers.

ALEX: JPMorgan posted net income of $16.9 billion, EPS of $6.14, and a return on tangible common equity of 23%. Strip out some one-off items and revenue was actually up 15% year-over-year.

JORDAN: And that growth was really broad-based — markets revenue was the biggest driver, but you also had higher asset management fees, stronger investment banking revenue, and higher deposit and loan balances. The one drag was lower rates, but honestly, that barely made a dent.

ALEX: Expenses climbed too — $27.3 billion, up 15%, mostly tied to volume and revenue-related costs plus front-office hiring. Credit costs came in at $2.5 billion. And here's a nice surprise for investors: the board is bumping the quarterly dividend up to $1.65 a share starting next quarter.

JORDAN: Let's talk about the business lines, because two of them really stood out. The CIB — that's the Corporate and Investment Bank — had a monster quarter. Revenue up 27% year-over-year, investment banking fees up 30%, with double-digit growth across the board.

ALEX: And equities trading? Up 86% year-over-year. Eighty-six percent, Jordan.

JORDAN: That's the kind of number that makes you sit up. CFO Jeremy Barnum was pretty candid on the call though — he said this level of equities strength is "a little bit hard to imagine being repeated." So management itself is tapping the brakes on extrapolating this quarter forward.

ALEX: Right, and same with investment banking — some of that came from large deals getting pulled forward and a couple of high-profile IPOs. But he also said the pipeline remains "quite robust," and there's this interesting dynamic where the buzz around big deals seems to be generating even more activity.

JORDAN: Meanwhile, on the asset and wealth management side, AUM hit $5.1 trillion, up 18%, with $50 billion in long-term net inflows. And in consumer banking, they added over 500,000 net new checking accounts this quarter. That's a franchise that's just quietly compounding.

ALEX: Let's get into the bigger story of the call, though — the leadership news. JPMorgan just elevated Doug and Troy to co-presidents, and long-time consumer banking head Marianne Lake is retiring as a result.

JORDAN: This dominated the Q&A. Analysts kept probing Jamie Dimon about succession, and he was pretty firm that the timetable for his own tenure "hasn't changed" — still talking in terms of a few years, plus or minus, with the board ultimately deciding.

ALEX: One exchange I loved — Mike Mayo basically said, half-joking, "you've now got an FX trader running the consumer bank," referring to Troy. Barnum jumped in to correct him: Troy was actually an options trader, not FX. Small detail, but it got a laugh.

JORDAN: Dimon's broader point was that he wants leaders who've operated across the whole company, not just people who came up through investment banking. He was pretty explicit that leaders who only understand trading or dealmaking can end up neglecting the rest of the franchise.

ALEX: Let's talk guidance, because they raised it meaningfully. Full-year NII outlook ex-Markets moved up

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: BANKS (https://betafinch.com/groups/BANKS)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, bringing you the numbers and the narrative behind them. I'm Alex.

JORDAN: And I'm Jordan. And Alex, we've got Goldman Sachs Q2 2026, and this one's a doozy.

ALEX: It really is — but before we dive in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good, let's get into it. Record quarter, full stop. $20.3 billion in net revenues, record EPS of $20.98, ROE of 23.5%, ROTE of 25.5%. Those are eye-popping numbers for a bank this size.

ALEX: Every single segment contributed. Global Banking & Markets alone hit a record $15.5 billion. Advisory revenue up 17% year-over-year — and get this, Goldman crossed $1 trillion in announced M&A volume in just six months, first bank ever to do that.

JORDAN: And they're not just winning deals, they're winning them by a mile. $425 billion ahead of the next closest competitor in announced M&A. That's not a lead, that's a lap.

ALEX: Equity underwriting revenue up 130%, debt underwriting up 75% — best quarter on record there. A lot of that tied to marquee names too — they were lead bookrunner on the SpaceX IPO and the Alphabet equity raise.

JORDAN: But honestly, the number that made me do a double-take was equities trading. Record $7.4 billion, with intermediation revenue up 60% and equity financing up 91%. CFO Denis Coleman basically said this is the payoff from a multi-year bet on building out their Asia prime brokerage business.

ALEX: Right, and analysts pushed hard on that in Q&A — is this sustainable, or is it a couple of huge clients driving the number? Coleman pushed back, saying it's broad-based across long-short and quant clients globally, not concentrated in a handful of accounts.

JORDAN: FICC was strong too — $4.6 billion, up 32%, with financing revenue hitting a record. Across FICC and equities combined, financing now makes up 37% of total revenue there. Goldman's essentially been turning its balance sheet into a growth engine.

ALEX: Let's talk Asset & Wealth Management, because that story's just as interesting. Revenue up 20% year-over-year to $4.6 billion, 34th straight quarter of long-term net inflows, total assets under supervision crossed $4 trillion for the first time.

JORDAN: And alternatives fundraising — $59 billion in the quarter, $85 billion year-to-date. They actually raised their full-year fundraising guidance to over $125 billion. $31 billion of that was private credit alone this quarter.

ALEX: They also picked up two massive OCIO mandates — Verizon and Lockheed Martin's retirement plans, $70 billion combined in assets. That's the kind of sticky, fee-generating business that makes this segment more durable over time.

JORDAN: Now, the through-line for this whole call was really the AI infrastructure buildout. CEO David Solomon kept coming back to it — data centers, energy, chips, the whole ecosystem is pulling in capital far beyond traditional tech financing, and Goldman's positioning itself as the plumbing for that capital.

ALEX: He was refreshingly honest about the risk side too. When asked directly about bubble concerns, Solomon said, essentially, "I'm not smart enough to tell you if there's a recalibration coming in six or eighteen months, but over three to five years, we're investing in long-term growth." He didn't dodge the question, but he didn't overpromise either.

JORDAN: That was a theme all call — a lot of "this won't be a straight line, there'll be bumps." Which, from a bank CEO in the middle of a record quarter, is actually a pretty disciplined thing to say out loud.

ALEX: One more Q&A moment worth flagging — Mike Mayo asked about the "multiplier eff

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: BANKS (https://betafinch.com/groups/BANKS)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown, bringing you the numbers, the color, and the context you actually need. I'm Alex, joined as always by Jordan. Today: Citigroup's Q2 2026.

JORDAN: Before we get into it, quick note from us — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Right, let's get into it. Citi just posted its best quarterly revenue in a decade. Net income of $5.8 billion, EPS of $3.15, ROTCE of 13%, on $24.8 billion in revenue, and here's the kicker — over 9% positive operating leverage. That means revenue grew way faster than expenses.

JORDAN: And it wasn't one lucky business carrying the firm — double-digit revenue growth in four of five segments. Services had its best quarter ever, over 30% returns. Markets crossed $7 billion again, up 17%, with equities up a stunning 40-plus percent on prime balances jumping nearly 60%. Banking revenue climbed 34%, investment banking up 44% — they had lead roles on marquee IPOs like SpaceX and Cerebras.

ALEX: Wealth notched its ninth straight quarter of growth, up 13%, returns now over 14%. The one soft spot was U.S. Consumer Cards — heavy investment spend, including that American Airlines-Barclays portfolio acquisition, weighed on operating leverage there, even though ROTCE for cards actually rose to 22%.

JORDAN: So strong quarter across the board, and yet — the stock dropped about 5% on the print. That's the real story here.

ALEX: Exactly, and it all comes down to guidance. CFO Gonzalo Luchetti kept the full-year ROTCE target at 10-11%, even after hitting 13.1% year-to-date. Analysts did the math out loud — Glenn Schorr and Mike Mayo both pressed hard on this. If you're at 13% for the first half, holding 10-11% for the year implies a real step-down in the second half.

JORDAN: And management's answer was essentially: some of that's normal seasonality — markets revenue historically drops about 20% between first and second half — but a lot of it is a deliberate choice. They said if the environment stays strong, they're going to lean in and accelerate investments and severance actions rather than just let the extra profit flow to the bottom line this year.

ALEX: Jane Fraser put it bluntly: "This is 100% offense." They're not defending market share or patching up legacy systems — they're pulling forward spending on things like AI, technology, marketing in cards, and structural efficiency work to lock in higher, more durable returns in 2027 and beyond.

JORDAN: It's a "spend the windfall now" strategy. They already took $800 million in severance in just the first half — matching all of last year — and signaled there could be more in the second half if opportunities arise.

ALEX: On the balance sheet side, capital looks solid. CET1 ratio at 12.8%, well above their regulatory minimum. They announced a 12% dividend increase and are running a $30 billion buyback program, having already repurchased $4 billion this quarter.

JORDAN: Credit quality was also a bright spot — corporate credit stayed clean, and even in cards, delinquencies and losses came in better than expected. Consumer spending looked resilient, up 6-7% even excluding the new airline card portfolio.

ALEX: There were a couple of housekeeping items too — Jenn Landis wrapped up her run as head of Investor Relations to become CFO of the Markets business, handing the reins to Margo Pilic. And Citi continues unwinding its Mexico business, Banamex — they've now sold down over 49% of that stake, with full deconsolidation expected in early 2027.

JORDAN: The other big theme was AI — not as a buzzword, but operationally. Nearly nine in ten Citi employees are using their internal AI tools

This episode includes AI-generated content.